- Home
- QLGN vs SLRX Comparison
QLGN vs SLRX Comparison
Compare QLGN & SLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- QLGN
- SLRX
- Stock Information
- Founded
- QLGN 1996
- SLRX N/A
- Country
- QLGN United States
- SLRX United States
- Employees
- QLGN N/A
- SLRX N/A
- Industry
- QLGN Biotechnology: Pharmaceutical Preparations
- SLRX Biotechnology: Pharmaceutical Preparations
- Sector
- QLGN Health Care
- SLRX Health Care
- Exchange
- QLGN Nasdaq
- SLRX Nasdaq
- Market Cap
- QLGN 3.1M
- SLRX 2.9M
- IPO Year
- QLGN N/A
- SLRX N/A
- Fundamental
- Price
- QLGN $2.26
- SLRX $5.56
- Analyst Decision
- QLGN
- SLRX
- Analyst Count
- QLGN 0
- SLRX 0
- Target Price
- QLGN N/A
- SLRX N/A
- AVG Volume (30 Days)
- QLGN 209.6K
- SLRX 286.4K
- Earning Date
- QLGN 11-13-2025
- SLRX 11-13-2025
- Dividend Yield
- QLGN N/A
- SLRX N/A
- EPS Growth
- QLGN N/A
- SLRX N/A
- EPS
- QLGN N/A
- SLRX N/A
- Revenue
- QLGN N/A
- SLRX N/A
- Revenue This Year
- QLGN N/A
- SLRX N/A
- Revenue Next Year
- QLGN N/A
- SLRX N/A
- P/E Ratio
- QLGN N/A
- SLRX N/A
- Revenue Growth
- QLGN N/A
- SLRX N/A
- 52 Week Low
- QLGN $1.61
- SLRX $4.50
- 52 Week High
- QLGN $10.45
- SLRX $108.00
- Technical
- Relative Strength Index (RSI)
- QLGN 62.69
- SLRX 43.47
- Support Level
- QLGN $1.95
- SLRX $4.79
- Resistance Level
- QLGN $2.16
- SLRX $5.90
- Average True Range (ATR)
- QLGN 0.18
- SLRX 0.40
- MACD
- QLGN 0.08
- SLRX 0.27
- Stochastic Oscillator
- QLGN 43.17
- SLRX 75.36
About QLGN Qualigen Therapeutics Inc.
Qualigen Therapeutics Inc is an early-clinical-stage therapeutics company focused on developing treatments for adult and pediatric cancer. The company's business consists of one early-clinical-stage therapeutic program (QN-302) and one preclinical therapeutic program. The company's program, QN-302, is an investigational small-molecule G-quadruplexes (G4)-selective transcription inhibitor with binding affinity to G4s prevalent in cancer cells.
About SLRX Salarius Pharmaceuticals Inc.
Salarius Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing effective treatments for cancers with high, unmet medical needs. The company has focused on two classes of drugs that address gene dysregulation: targeted protein inhibitors and targeted protein degradation. Its Pipeline includes seclidemstat (SP-2577), a small molecular inhibitor, and SP-3164, a small molecular protein degrader.